ANIP vs. VKTX, ETNB, AUPH, BHVN, KNSA, OPK, MIRM, XNCR, MRUS, and GERN
Should you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include Viking Therapeutics (VKTX), 89bio (ETNB), Aurinia Pharmaceuticals (AUPH), Biohaven (BHVN), Kiniksa Pharmaceuticals (KNSA), OPKO Health (OPK), Mirum Pharmaceuticals (MIRM), Xencor (XNCR), Merus (MRUS), and Geron (GERN). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
Viking Therapeutics presently has a consensus price target of $30.25, indicating a potential upside of 173.26%. ANI Pharmaceuticals has a consensus price target of $71.67, indicating a potential upside of 23.44%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than ANI Pharmaceuticals.
Viking Therapeutics received 162 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 79.75% of users gave Viking Therapeutics an outperform vote while only 64.25% of users gave ANI Pharmaceuticals an outperform vote.
In the previous week, ANI Pharmaceuticals had 2 more articles in the media than Viking Therapeutics. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 2 mentions for Viking Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.95 beat Viking Therapeutics' score of 0.90 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -1.29%. Viking Therapeutics' return on equity of 15.77% beat ANI Pharmaceuticals' return on equity.
ANI Pharmaceuticals has higher revenue and earnings than Viking Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.
78.1% of Viking Therapeutics shares are held by institutional investors. Comparatively, 69.8% of ANI Pharmaceuticals shares are held by institutional investors. 4.4% of Viking Therapeutics shares are held by company insiders. Comparatively, 28.5% of ANI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Viking Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
Viking Therapeutics and ANI Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get ANI Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ANI Pharmaceuticals Competitors List
Related Companies and Tools